Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents.

Next Previous
Trial Profile

A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary) ; Insulin aspart/insulin protamine aspart; Insulin neutral protamine lispro/insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GALAPAGOS
  • Sponsors Sanofi

Most Recent Events

  • 01 Apr 2018 Results of pooled analysis of Asian patients included in this and other six trials assessing the impact of patient baseline covariates on the required dose of basal insulin and treatment response for the improved management of Asian patients with type 2 diabetes published in the Diabetes Therapy
  • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
  • 15 Mar 2013 New source identified and integrated (Clinical Trials Registry - India; CTRI2010-091-001386).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top